DBV Technologies S.A. (DBVT) – What Are Investment Firms Saying About This Stock?

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $48.50.

Several equities analysts have recently weighed in on the company. Weiss Ratings downgraded DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of DBV Technologies in a research note on Thursday, September 10th. Citizens Jmp boosted their price target on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 30th. Citigroup reiterated a “market outperform” rating on shares of DBV Technologies in a report on Wednesday, September 30th. Finally, Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th.

Hedge Funds Weigh In On DBV Technologies

A number of institutional investors have recently added to or reduced their stakes in DBVT. Perceptive Advisors LLC acquired a new position in shares of DBV Technologies during the 1st quarter valued at about $20,146,000. Vivo Capital LLC boosted its position in shares of DBV Technologies by 8.4% during the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after purchasing an additional 205,943 shares during the period. ADAR1 Capital Management LLC acquired a new stake in DBV Technologies in the 1st quarter valued at approximately $21,159,000. Royal Bank of Canada increased its holdings in DBV Technologies by 167.1% in the 1st quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock valued at $98,000 after purchasing an additional 2,928 shares during the last quarter. Finally, Elmind Capital LP purchased a new stake in shares of DBV Technologies in the 1st quarter valued at $5,536,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Trading Down 1.8%

NASDAQ:DBVT opened at $8.87 on Thursday. DBV Technologies has a 12 month low of $8.86 and a 12 month high of $26.18. The stock has a 50 day moving average of $12.59 and a two-hundred day moving average of $15.93. The firm has a market cap of $557.73 million, a P/E ratio of -2.53 and a beta of -1.04.

About DBV Technologies

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s technology is designed to deliver therapeutic proteins through the skin without needles, with the goal of gradually modifying the immune system’s response to specific allergens.

DBV Technologies’ principal product candidate is Viaskin Peanut, an investigational epicutaneous immunotherapy designed to expose patients to small amounts of peanut protein through a wearable patch.